Finch Therapeutics Group (FNCH) Competitors $12.75 +0.25 (+2.00%) As of 05/1/2025 03:14 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsTrendsBuy This Stock FNCH vs. CNTX, GALT, EPIX, IGMS, AVTE, JSPR, UNCY, TIL, MNOV, and IVVDShould you be buying Finch Therapeutics Group stock or one of its competitors? The main competitors of Finch Therapeutics Group include Context Therapeutics (CNTX), Galectin Therapeutics (GALT), ESSA Pharma (EPIX), IGM Biosciences (IGMS), Aerovate Therapeutics (AVTE), Jasper Therapeutics (JSPR), Unicycive Therapeutics (UNCY), Instil Bio (TIL), MediciNova (MNOV), and Invivyd (IVVD). These companies are all part of the "pharmaceutical products" industry. Finch Therapeutics Group vs. Context Therapeutics Galectin Therapeutics ESSA Pharma IGM Biosciences Aerovate Therapeutics Jasper Therapeutics Unicycive Therapeutics Instil Bio MediciNova Invivyd Context Therapeutics (NASDAQ:CNTX) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability, risk and community ranking. Does the media refer more to CNTX or FNCH? In the previous week, Context Therapeutics had 12 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 13 mentions for Context Therapeutics and 1 mentions for Finch Therapeutics Group. Context Therapeutics' average media sentiment score of 0.79 beat Finch Therapeutics Group's score of 0.00 indicating that Context Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Context Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Finch Therapeutics Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger earnings & valuation, CNTX or FNCH? Context Therapeutics has higher earnings, but lower revenue than Finch Therapeutics Group. Context Therapeutics is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioContext TherapeuticsN/AN/A-$23.96M-$0.49-1.76Finch Therapeutics Group$110K186.15-$74.75M-$8.82-1.45 Which has more risk and volatility, CNTX or FNCH? Context Therapeutics has a beta of 2.18, meaning that its share price is 118% more volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Do insiders and institutionals believe in CNTX or FNCH? 14.0% of Context Therapeutics shares are owned by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are owned by institutional investors. 3.0% of Context Therapeutics shares are owned by company insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the MarketBeat Community favor CNTX or FNCH? Context Therapeutics received 17 more outperform votes than Finch Therapeutics Group when rated by MarketBeat users. Likewise, 79.41% of users gave Context Therapeutics an outperform vote while only 52.63% of users gave Finch Therapeutics Group an outperform vote. CompanyUnderperformOutperformContext TherapeuticsOutperform Votes2779.41% Underperform Votes720.59% Finch Therapeutics GroupOutperform Votes1052.63% Underperform Votes947.37% Is CNTX or FNCH more profitable? Context Therapeutics' return on equity of -58.76% beat Finch Therapeutics Group's return on equity.Company Net Margins Return on Equity Return on Assets Context TherapeuticsN/A -58.76% -55.80% Finch Therapeutics Group N/A -69.14%-26.92% Do analysts prefer CNTX or FNCH? Context Therapeutics presently has a consensus price target of $6.17, indicating a potential upside of 614.98%. Given Context Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Context Therapeutics is more favorable than Finch Therapeutics Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Context Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryContext Therapeutics beats Finch Therapeutics Group on 13 of the 17 factors compared between the two stocks. Get Finch Therapeutics Group News Delivered to You Automatically Sign up to receive the latest news and ratings for FNCH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FNCH vs. The Competition Export to ExcelMetricFinch Therapeutics GroupBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.48M$2.95B$5.53B$7.93BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-1.4530.0722.5118.54Price / Sales186.15494.82397.62103.30Price / CashN/A168.6838.1834.62Price / Book0.893.176.734.25Net Income-$74.75M-$72.35M$3.22B$248.18M7 Day Performance1.19%2.14%1.38%1.03%1 Month Performance-10.53%5.67%2.79%2.70%1 Year Performance412.05%-23.57%15.41%4.05% Finch Therapeutics Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FNCHFinch Therapeutics GroupN/A$12.75+2.0%N/A+451.9%$20.48M$110,000.00-1.45190News CoverageGap DownHigh Trading VolumeCNTXContext Therapeutics1.9169 of 5 stars$0.88-6.3%$6.17+600.4%-37.3%$78.98MN/A-0.977Analyst ForecastAnalyst RevisionNews CoverageGALTGalectin Therapeutics1.2897 of 5 stars$1.25-5.3%$11.00+780.0%-62.9%$78.98MN/A-1.719EPIXESSA Pharma3.1616 of 5 stars$1.77-1.1%$9.50+436.7%-73.3%$78.57MN/A-2.5750Positive NewsIGMSIGM Biosciences4.3508 of 5 stars$1.31+0.8%$5.50+319.8%-85.9%$78.31M$2.68M-0.36190Upcoming EarningsNews CoverageAVTEAerovate Therapeutics1.4462 of 5 stars$2.68-0.2%$2.25-15.9%-98.7%$77.54MN/A-0.8920Earnings ReportEx-DividendHigh Trading VolumeJSPRJasper Therapeutics2.2939 of 5 stars$5.15+7.3%$62.50+1,113.6%-77.6%$77.36MN/A-1.0920News CoveragePositive NewsUNCYUnicycive Therapeutics3.7697 of 5 stars$0.64-0.7%$5.50+754.0%-42.7%$77.09M$680,000.00-0.669Short Interest ↓Positive NewsTILInstil Bio3.3763 of 5 stars$11.72-5.8%$114.00+872.7%+17.6%$76.87MN/A-1.01410Upcoming EarningsPositive NewsMNOVMediciNova1.8513 of 5 stars$1.57+0.3%$9.00+475.1%+14.0%$76.76M$1M-6.8010Upcoming EarningsAnalyst ForecastShort Interest ↓News CoverageIVVDInvivyd3.5509 of 5 stars$0.64-4.0%$7.52+1,083.0%-74.9%$76.22M$25.38M-0.32100Upcoming EarningsShort Interest ↓News CoverageGap Up Related Companies and Tools Related Companies CNTX Alternatives GALT Alternatives EPIX Alternatives IGMS Alternatives AVTE Alternatives JSPR Alternatives UNCY Alternatives TIL Alternatives MNOV Alternatives IVVD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FNCH) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Finch Therapeutics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Finch Therapeutics Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
